



Robert Greene Sterne Jorge A. Goldstein David K.S. Cormwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherston Timothy J. Shea, Jir Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowith

Brian J. Del Buono Mark Fox Evers Vincent L. Capuano Elizabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Edward W. Yee Grant E. Reed Virgil Lee Beaston Theodore A. Wood Joseph S. Ostroff Jason D. Eisenberg Tason D. Eisenberg Tason B. Wight LuAnne M. DeSantis Ann E. Summerfilo Ann E. Summerfilo Helene C. Carfson Cynthia M. Bouchez Imothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir MS. Aii Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou Young Tan W. Blake Coblentz' James J. Pohl John J. Haran Mark W. Rygiel Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler
Bryan L. Skelton*
Paul A. Cabn,
Robert A. Schwartzmar
C. Matthew Rozier
Alexandra K. Pechhold
Registered Patent Ager
Karen R. Markowicz
Matthew J. Dowd

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Julie A. Heider Mita Mukherjee Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

of Counsel dward J. Kessler Genneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

April 9, 2007

WRITER'S DIRECT NUMBER: (202) 772-8834 INTERNET ADDRESS: BHAANES@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Art Unit 1644 Attn: Mail Stop Amendment

Re:

U.S. Utility Patent Application

Application No. 10/529,221; Filed: June 30, 2006

For: Targeted CD1d Molecules

Inventors:

ROBERT et al.

Our Ref:

1843.0200001/EKS/EJH

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Second Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97(b);
- 2. Form PTO/SB/08A (1 sheet) listing 4 documents (US14 and FP16-FP18);
- 3. Form PTO/SB/08B (1 sheet) listing 1 document (NPL92);
- 4. Copies of cited documents (FP16-FP18 and NPL92); and
- 5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox P.L.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents April 9, 2007 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Elizabeth J. Haanes, Ph.D. Attorney for Applicants Registration No. 42,613

EJH/cms Enclosures

661965_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ROBERT et al.

Appl. No.: 10/529,221

Filed: June 30, 2006

For: **Targeted CD1d Molecules** Confirmation No.: 2116

Art Unit:

1644

Examiner:

DIBRINO, Marianne N.

Atty. Docket: 1843.0200001/EKS/EJH

Second Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on August 15, 2006 in connection with the above-captioned application.

Copies of documents FP16 to FP18 and NPL92 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of the U.S. patent publication cited on the attached Form PTO/SB/08A, document US14, is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Second Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Elizabeth J. Haanes, Ph.D. Attorney for Applicants

Registration No. 42,613

Date

1100 New York Avenue, N.W.

Washington, D.C. 20005-3934

(202) 371-2600

641725v1

APR 0 9 2007 55

Sheet

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

Attorney Docket Number

Substitute for form 1449/PTO

TRAPIRST SUPPLEMENTAL

INFORMATION DISCLOSURE

(Use as many sheets as necessary)

STATEMENT BY APPLICANT

of

Filing Date	June 30, 2006	
First Named Inventor	ROBERT, Bruno	
Art Unit	1644	
Examiner Name	DIBRINO, Marianne N.	

10/529,221

1843.0200001/EKS/HCC

Complete if Known

Equivalent of Form PTO/SB/08A (09-06)

			U.S. PATENT DO	OCUMENTS	1 100000
Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
mitiais		Number-Kind Code ^{2 (If Known)}			
	US14	2002/0071842 A1	06/13/2002	Gumperz et al.	
					<u> </u>
`					
	ļ				
			-	·	

	-	FC	REIGN PATENT DO	OCUMENTS	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			T ⁶
	FP16	WO 01/71005 A2	09/27/2001	Kufer, P.	
	FP17	WO 01/78768 A2	10/25/2001	University of Rochester	
	FP18	WO 01/90198 A1	11/29/2001	Ludwig Institute for Cancer Research	

641705v1

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

Equivalent of Form PTO/SB/08B (09-06) Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Shostitute for form 1449/PTO		Complete if Known		
FIRST SUPPLEMENTAL		Application Number	10/529,221	
		Filing Date	June 30, 2006	
INFORMATION DISCLO		First Named Inventor	ROBERT, Bruno	
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1644	
		Examiner Name	DIBRINO, Marianne N.	
Sheet 1 of	1	Attorney Docket Number	1843.0200001/EKS/HCC	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Wilson, M.T., et al., "Immunotherapy with ligands of natural killer T cells," Trends Mol. Med. 8:225-231, Elsevier Science Ltd. (May 2002)		
	NPL92			
-				
		·		
641712v1	L	<u> </u>	<u> </u>	

Date Examiner

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.